Eurofins Discovery is a leader in translational biology and phenotypic approaches, with cell-based functional assays that empower our clients worldwide with a human-focused approach to drug discovery.
Human phenotypic approaches have reemerged as a powerful screening and profiling technique for prioritizing hits and lead candidates, elucidating novel mechanisms of action, and developing commercially successful therapeutics for unmet medical needs. Because these in vitro, human primary cell models mimic human disease states, and therefore patients, their importance to integrated discovery programs and drug discovery more broadly, is widely recognized. This includes an increasing acceptance of non-animal alternatives by regulatory agencies. The renaissance in translational, phenotypic assays using in vitro approaches is here—easing clinical translation and expediting drug development programs.
At Eurofins Discovery, our Translational Biology Center of Excellence is driving the phenotypic drug discovery renaissance forward with human translational cell models for important therapeutic areas in oncology, immunology, fibrosis and cardiovascular disease. Our translational biology assays are reflective of specific clinical outcomes, with optimized cell types, culture conditions, formats, and endpoints for relevance to the human clinical data you care most about. Working together in partnership, we can empower confident decision-making early and throughout the drug discovery process, helping you choose the best candidates for further development or to identify drug repurposing opportunities. Select assays in additional species are available.
Our Translational Biology Center of Excellence, with a team of experts and state-of-the-art facilities, helps you navigate your way to successful drug discovery with robust platforms, powerful analytics, cross-platform collaborations, and Custom Services. We’ve been a global leader in human phenotypic drug discovery services since 2000—advancing candidate pipelines for over 500 clients. Dive in to learn more about our expanding portfolio of assays and services.
Streamline Clinical Translation with Results Closer to Clinical Outcomes
Key Areas
BioMAP Platform
The BioMAP® Platform provides response profiles in human primary cell-based disease models. A robust reference database powers advanced analytics.
OncoPanel Platform
Features 2D or 3D spheroid cancer models with genomic tools for evaluation of innovations and combinations.
Biomarker Services
Evaluate mechanistic and functional readouts. By testing candidates in diverse cellular contexts with ELISA, Alpha LISA™, Meso Scale Discovery®, Luminex, and more.
Immune Response Models
Small molecule or biotherapeutics assessment on adaptive immunity with BioMAP T Cell Autoimmune Panel, Cytokine Storm, and AdapTive models.
Translational Cell Models
Development of primary cell models from human diseased and normal tissues. Functional readouts support clients from screening to lead optimization.
Cancer Cell Models
Not just about variety, these assays are about context, with 3D spheroids, tumor microenvironment models for immuno-oncology, and cell migration assays.
In Vitro Models
Our robust BioMAP® Platform is the anchor to this powerhouse portfolio that includes neurite outgrowth and angiogenesis tube formation assays.
Immune Cell Activity
Assays complementary to our more complex human primary cell co-culture models, including STING and a breadth of Toll-like Receptor assays.
Applications
Strategies for resistance & sensitivity assessment, combination evaluation, repurposing, and competitive benchmarking.
Toxicity Signatures and Safety Profiling
Critical and early identification of toxicities and adverse outcome risks with BioMAP® Toxicity Signature Analysis and cytokine release assay strategies.
Full-Time Equivalent (FTE) Scientific Services
Eurofins Discovery offers a broad collection of standard and custom assays to meet the needs of every biology program.
Gene Expression Assays
Compound screening in cell-based gene expression assays utilizing Fluidigm microfluidics-based qPCR technology
Phagocytosis and Efferocytosis Assays
In vitro models of pro-inflammatory phagocytosis and anti-inflammatory efferocytosis are available for compound screening by High-content Imaging.
FAQS
Related Resources
Related Solutions
FAQS
Phenotypic assays evaluate a test agent by looking at its effect on specific biological endpoints, which may themselves be modulated by a number of different mechanisms or biological pathways. Examples include tumor cell viability, cytokine secretion from immune cells, and toxicities. This contrasts with target-based assays, which are also known as target engagement or mechanistic assays and focus on a specific biological target and its immediate function. Examples include kinase substrate phosphorylation and ligand-induced receptor internalization. While target-based assays inform on the specific activity of test agent at a given target, phenotypic assays inform on the broader consequences of a test agent’s action, often from a disease state perspective. However, both assay types are powerful and have complementary roles in drug discovery.
Please contact your local BD or our team for assistance at ClientServicesStCharles@discovery.eurofinsus.com
Please speak with our Head of Biology or Study directors at ClientServicesStCharles@discovery.eurofinsus.com
We proudly offer e-commerce capabilities to our customers
Please sign in to your online account or create a new online account at https://apac.eurofinsdiscovery.com/usermanagement/login?returnUrl=%2Fresources
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
